DecisionDx-Melanoma continues to demonstrate strong performance in helping physicians make more informed, risk-aligned ...

A gene expression-based test identifies patients with primary cutaneous melanoma at a lower or higher risk for sentinel lymph ...

Researchers have found in a new study that in early-stage cervical cancer, sentinel lymph node biopsy (SLNB) alone was ...

Castle Biosciences (CSTL) announced new data demonstrating the clinical value of its DecisionDx-Melanoma test in improving sentinel lymph node ...

Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...

Lymphatic mapping, a recent technique first developed for the management of melanoma, is based on the concept that information about the status of the entire lymphatic drainage from a tumor site could ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

University of Queensland researchers have received a $3.1 million grant for a trial which could revolutionize endometrial cancer treatment. Research Director Professor Andreas Obermair at UQ's ...

Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen treatment burdens. University of Pittsburgh and UPMC Hillman Cancer Center ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating ...